Canada: The TPP — New Rights For Pharmaceutical Patent Holders In Canada

The Canadian government released the official consolidated text of the Trans-Pacific Partnership (TPP) agreement on Nov., 5, 2015.1 This follows the technical summary of negotiated outcomes posted on the Department of Foreign Affairs and Development Canada's website following conclusion of the agreement.2

The Canadian government has not released any additional information as to how it will apply the TPP in Canada.  However, based on a review of the text of the TPP, patent holders can look forward to some additional patent rights, notably patent term extensions in certain situations. No changes are expected regarding patentable subject matter.4

Moreover, the TPP includes specific provisions for the pharmaceutical industry including explicit data protection for a broad range of pharmaceuticals, including new chemical entity based pharmaceuticals, clinical data for previously approved products, and biologics.5 The TPP also includes provisions on patent linkage and early working exceptions for regulatory approval for pharmaceuticals.6

The Canadian government has stated Canada complies with many of the provisions of the TPP, but it has not yet commented on all provisions.7 Thus, questions exist regarding the scope of patent term extension that Canada will provide and how the data protection provisions will be implemented in Canada.

Below is a review of the TPP provisions related to patents and pharmaceuticals, and how they compare to the existing regime in Canada. Changes related to copyright and trade secret laws are also on the way and discussed in a separate article.

The agreement has not yet been ratified and the new Canadian government has stated it will engage Parliament in a consultation on the TPP. The issues raised for pharmaceutical stakeholders as a result are also addressed.

TPP provisions for patents

Patent Term Extension

The most apparent change for patents under the TPP is the introduction of two categories of patent term extension; namely, (1) patent term extension owing to delays in processing patent applications at the patent office, and (2) specifically for pharmaceutical patents, extension owing to delays in obtaining marketing or regulatory approval. 

i.  Patent Office Delays

For patent office delays, the TPP requires that patent terms shall be extended where "unreasonable delays" occur in application processing, meaning, more than five years from the filing date or more than three years after a request for examination of an application.8

At this time there is no indication of how long the patent term will be extended over such delays. The Canadian government has not commented on these provisions, and the TPP itself is silent as to the length of additional patent protection to be granted.9

ii.  Regulatory or Marketing Approval Delays for Pharmaceutical Patents

The TPP also grants patent term extension to pharmaceutical patents impacted by "unreasonable curtailment" or delay in obtaining regulatory or marketing approval.10

At this time there is no indication of how long the delay in obtaining approval must be before a patent is entitled to a term extension. The TPP provides no definition of "unreasonable curtailment" nor does it give any indication as to how long the delay must be to merit an extension.11 The Canadian government has also not commented on what it would consider to be an "unreasonable curtailment" that would qualify for a patent term extension.12

Where there is an "unreasonable curtailment", the TPP provides that sui generis patent extension is to be granted.13  Canada has stated that the sui generis patent term restoration granted under the TPP is in line with extensions it negotiated for such delays under the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union, meaning a two year cap on additional protection and flexibility to maintain its export exception.14

Patentable Subject Matter

Under the TPP, patents must be granted for inventions that are new, involve an inventive step (meaning not obvious), and are capable of industrial application (meaning useful).15 Eligible exclusions for patentable subject matter are: (1) diagnostic, therapeutic, or surgical methods of treatment in humans or animals, (2) animals and plants, other than microorganisms, and (3) biological processes for the production of plants or animals.16

The Canadian government has stated the patentable subject matter provisions in the TPP, including criteria for patentability exclusion, comply with Canada's existing laws and regimes.17

TPP provisions for pharmaceuticals 

Data Protection

For pharmaceutical products, the TPP also includes provisions for the protection of undisclosed safety and efficacy test data submitted by the manufacturer of an innovative pharmaceutical product as required to obtain regulatory or marketing approval. Distinct from patent protection, data protection prevents manufacturers of the same or similar products from referencing an innovator's data submitted for marketing approval for specified periods of time.

The TPP provides for three main categories of data protection: (1) new chemical entity based pharmaceutical products, (2) clinical data, and (3) biologics, for previously approved pharmaceutical products. The Canadian government, however, has provided limited information regarding how the data protection provisions will be implemented.18

i.  New pharmaceutical products – chemical entity based

Under the TPP, manufacturers seeking approval to market a "same or similar" product to a "new" pharmaceutical product cannot reference the undisclosed safety and efficacy test data of the new pharmaceutical product for at least five years from the date marketing approval was first granted.19

Canada has not commented on how it will apply this provision. However, Canada's existing regime of extending data protection to eligible "innovative drugs" appears to surpass the minimum outcomes agreed to under the TPP. Under the Food and Drug Regulations, a drug is eligible for up to eight years of data protection if it contains a medicinal ingredient not previously approved and is not a variation of a previously approved medicinal ingredient.20 Since the TPP defines a "new pharmaceutical product" as one that does not contain a previously approved chemical entity, these products appear to fall within the definition of "innovative drug" in Canada.21 

ii.  Clinical Data for previously approved pharmaceutical products

Under the TPP, new clinical information submitted for a new formulation, indication, or form of previously approved pharmaceutical products can benefit for up to three years of data protection.22

If implemented, this provision would allow for a new category of data that could benefit from data protection in Canada.  At present, such clinical data are not within Canada's existing data protection regime, which excludes data protection to previously approved pharmaceutical products, or variations thereof.23

However, it is not certain whether Canada will adopt this provision. Under the TPP, it appears to be an optional provision, while Canada has stated its existing laws and regimes for protection of clinical data are compliant.24

iii.  Biologics

For protection of undisclosed data for biologics, countries signing on to the TPP have a choice regarding the data protection they provide to manufacturers of innovative biologics. Under the TPP "effective market protection" must be granted to undisclosed data for either five years or eight years following the first market approval for new pharmaceutical products that are or contain a "biologic".25

While Canada has not commented on which TPP option it will choose for biologics, it appears both options satisfy Canada's current regime of extending data protection to eligible "innovative drugs" under the Food and Drug Regulations. The TPP defines a "biologic" as a product that is or contains a protein produced using biotechnological processes for use in humans for prevention, treatment or cure of a disease.26 As such they appear to fall within the definition of an innovative drug under the Food and Drug Regulations, and thus are eligible for up to eight years of data protection.

Patent Linkage and Early Working Exception

The TPP also includes provisions analogous to Canada's early working exception and regulatory regime for challenging pharmaceutical patents under the PM(NOC) Regulations. 27 

However, no major changes to the PM(NOC) Regulations are expected as a result of the TPP. Canada has stated the TPP provisions for patent linkage and regulatory review exceptions reflect existing laws and regimes.28

Issues for pharmaceutical stakeholders related to TPP application in Canada

Until ratification occurs, how Canada proceeds in implementing the TPP remains uncertain. The new Minister of International Trade has stated the government is committed to holding a full and open public debate in Parliament and to ensure Canadians are consulted on the TPP. 

Yet questions remain regarding the impact the TPP will have for pharmaceuticals in Canada. For example, will the TPP apply to issued patents or will it only apply to patents issued after ratification?<29 How will any enforcement provisions apply or change the law in Canada for pharmaceuticals, if at all? These questions cannot be answered without further clarification from the Canadian government.

Footnotes

Consolidated text of Trans-Pacific Partnership, online: Department of Foreign Affairs and International Trade 

Technical Summary of Negotiated Outcomes: Intellectual Property Chapter, online: Department of Foreign Affairs and International Trade

TPPsupra note 1, Art 18.46 & 18.48.

Ibid, Art 18.37; Technical Summarysupra note 2.

TPPsupra note 1, Art 18.50 & 18.52.

Ibid, Art 18.49 & 18.51.

Technical Summarysupra note 2.

TPPsupra note 1, Art 18.46.

TPPsupra note 1, Art 18.46; Technical Summarysupra note 2.

10 TPPsupra note 1, Art 18.48.

11 Ibid.

12 Technical Summarysupra note 2.

13 TPPsupra note 1, Art 18.48(2).

14 Comprehensive Economic and Trade Agreement, Canada and European Union, Ch 22, Art 9.2; Technical Summarysupra note 2.

15 TPPsupra note 1, Art 18.37.

16 TPPsupra note 1, Art 18.37(3)-(4).

17 Technical Summarysupra  note 2.

18 Technical Summarysupra  note 2.

19 TPPsupra note 1, Art 18.50.

20 Food and Drug Regulations, CRC, c 870, s C.08.004.1 (1)-(3) ["FDR"].

21 TPPsupra note 1, Art 18.53.

22 Ibid, Art 18.50(2)(a).

23 FDRsupra note 20, s C.08.004.1(1).

24 TPPsupra note 1, Art 18.50(2)(a)-(b); Technical Summarysupra  note 2.

25 TPPsupra note 1, Art 18.52(1).

26 Ibid, Art 18.52(2).

27 TPPsupra note 1, Art 18.49 and 18.51.

28 Technical Summarysupra note 2.

29 TPPsupra note 1, Art 18.10.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions